In colorectal cancer, GBP2 suppresses Wnt signaling, heightening sensitivity to paclitaxel and boosting survival rates, offering a therapeutic advantage for patients facing drug-resistant tumors by inhibiting beta-catenin-driven growth [35]. The gene discussed is GBP2; the disease is colorectal cancer.